The FDA's traditional review process is inadequate for generative AI, as it fails to address the unique challenges presented by this rapidly evolving technology in medicine.
Generative AI's potential in clinical settings is significant, but without a novel regulatory approach, we risk exposing patients to unsafe or ineffective treatments.
Collection
[
|
...
]